脂肪分泌的Slit2-C通过cAMP/PKA过渡抑制乳腺癌的侵袭
Haolin Hu1, Kexuan Li2, Lifei Han1
1Breast Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Molecular carcinogenesis
|April 2, 2025
概括
来自棕色脂肪的Slit2-C通过激活cAMP/PKA信号来减少乳腺癌的侵袭,促进表皮表型和发热. 这一途径为侵袭性乳腺癌提供了潜在的治疗点.
科学领域:
- 在瘤学瘤学.
- 代谢调节 代谢调节 代谢调节
- 细胞生物学 细胞生物学
背景情况:
- 脂肪组织的激活对乳腺癌的结果产生积极影响,与运动和通过棕色和色脂肪减肥相关.
- 脂肪组织在乳腺癌进展中的作用背后的精确机制尚未完全理解.
研究的目的:
- 阐明Slit2 (Slit2-C) 的C端片段在乳腺癌进展中的作用.
- 研究涉及Slit2-C对癌细胞影响的信号通路.
- 探索Slit2-C途径在侵袭性乳腺癌中的治疗潜力.
主要方法:
- 研究了Slit2-C对乳腺癌细胞入侵和上皮-介质细胞过渡 (EMT) 的影响.
- 使用特定抑制剂 (H89) 评估了cAMP/PKA信号通路的参与.
- 评估了癌细胞表型的变化,发热和Slit2-C过度表达的入侵.
主要成果:
- 通过抑制EMT,Slit2-C显著减少了乳腺癌细胞的入侵.
- 在乳腺癌细胞中,Slit2-C作为cAMP/PKA信号的积极调节者.
- 过度表达Slit2-C会增加表皮表型和发热,同时减少侵袭;这些效应被PKA抑制逆转.
结论:
- 在乳腺癌中,Slit2-C通过cAMP/PKA通路调解其抗侵袭作用.
- 切口2-C/cAMP/PKA轴代表了对侵袭性乳腺癌的有希望的治疗标.
- 调节Slit2-C可能为改善乳腺癌治疗结果提供一种新的策略.
更多相关视频
10:51Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
Published on: April 23, 2021
4.1K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.6K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
cAMP-dependent Protein Kinase Pathways
6.0K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
The JAK-STAT Signaling Pathway
8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.5K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
